Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114


18F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma.

Kong Z, Lin Y, Jiang C, Li L, Liu Z, Wang Y, Dai C, Liu D, Qin X, Wang Y, Liu Z, Cheng X, Tian J, Ma W.

Cancer Imaging. 2019 Aug 19;19(1):58. doi: 10.1186/s40644-019-0246-0.


Radiomics signature based on FDG-PET predicts proliferative activity in primary glioma.

Kong Z, Li J, Liu Z, Liu Z, Zhao D, Cheng X, Li L, Lin Y, Wang Y, Tian J, Ma W.

Clin Radiol. 2019 Oct;74(10):815.e15-815.e23. doi: 10.1016/j.crad.2019.06.019. Epub 2019 Jul 31.


A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication.

Wei J, Yang G, Hao X, Gu D, Tan Y, Wang X, Dong D, Zhang S, Wang L, Zhang H, Tian J.

Eur Radiol. 2019 Feb;29(2):877-888. doi: 10.1007/s00330-018-5575-z. Epub 2018 Jul 23.


Multiregional radiomics features from multiparametric MRI for prediction of MGMT methylation status in glioblastoma multiforme: A multicentre study.

Li ZC, Bai H, Sun Q, Li Q, Liu L, Zou Y, Chen Y, Liang C, Zheng H.

Eur Radiol. 2018 Sep;28(9):3640-3650. doi: 10.1007/s00330-017-5302-1. Epub 2018 Mar 21.


¹⁸F-fluorodeoxyglucose and ¹¹C-methionine positron emission tomography in relation to methyl-guanine methyltransferase promoter methylation in high-grade gliomas.

Choi H, Bang JI, Cheon GJ, Kim YH, Park CK, Park SH, Kang KW, Chung JK, Kim EE, Lee DS.

Nucl Med Commun. 2015 Mar;36(3):211-8. doi: 10.1097/MNM.0000000000000236.


A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.

Cheng W, Ren X, Cai J, Zhang C, Li M, Wang K, Liu Y, Han S, Wu A.

Oncotarget. 2015 Oct 6;6(30):29285-95. doi: 10.18632/oncotarget.4978.


18F-FDG-PET-based radiomics features to distinguish primary central nervous system lymphoma from glioblastoma.

Kong Z, Jiang C, Zhu R, Feng S, Wang Y, Li J, Chen W, Liu P, Zhao D, Ma W, Wang Y, Cheng X.

Neuroimage Clin. 2019;23:101912. doi: 10.1016/j.nicl.2019.101912. Epub 2019 Jun 27.


Noninvasive O6 Methylguanine-DNA Methyltransferase Status Prediction in Glioblastoma Multiforme Cancer Using Magnetic Resonance Imaging Radiomics Features: Univariate and Multivariate Radiogenomics Analysis.

Hajianfar G, Shiri I, Maleki H, Oveisi N, Haghparast A, Abdollahi H, Oveisi M.

World Neurosurg. 2019 Sep 7. pii: S1878-8750(19)32399-X. doi: 10.1016/j.wneu.2019.08.232. [Epub ahead of print]


Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis.

Han Y, Yan LF, Wang XB, Sun YZ, Zhang X, Liu ZC, Nan HY, Hu YC, Yang Y, Zhang J, Yu Y, Sun Q, Tian Q, Hu B, Xiao G, Wang W, Cui GB.

BMC Cancer. 2018 Feb 21;18(1):215. doi: 10.1186/s12885-018-4114-2.


Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.

Yuan G, Niu L, Zhang Y, Wang X, Ma K, Yin H, Dai J, Zhou W, Pan Y.

J Neurooncol. 2017 May;133(1):193-201. doi: 10.1007/s11060-017-2433-9. Epub 2017 May 17.


Predicting hypoxia status using a combination of contrast-enhanced computed tomography and [18F]-Fluorodeoxyglucose positron emission tomography radiomics features.

Crispin-Ortuzar M, Apte A, Grkovski M, Oh JH, Lee NY, Schöder H, Humm JL, Deasy JO.

Radiother Oncol. 2018 Apr;127(1):36-42. doi: 10.1016/j.radonc.2017.11.025. Epub 2017 Dec 19.


Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma.

Cheng W, Li M, Jiang Y, Zhang C, Cai J, Wang K, Wu A.

J Neurosurg. 2016 Jul;125(1):7-16. doi: 10.3171/2015.5.JNS142437. Epub 2015 Nov 6.


Radiomics analysis for the differentiation of autoimmune pancreatitis and pancreatic ductal adenocarcinoma in 18 F-FDG PET/CT.

Zhang Y, Cheng C, Liu Z, Wang L, Pan G, Sun G, Chang Y, Zuo C, Yang X.

Med Phys. 2019 Oct;46(10):4520-4530. doi: 10.1002/mp.13733. Epub 2019 Aug 13.


O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.

Kreth S, Thon N, Eigenbrod S, Lutz J, Ledderose C, Egensperger R, Tonn JC, Kretzschmar HA, Hinske LC, Kreth FW.

PLoS One. 2011 Feb 18;6(2):e17156. doi: 10.1371/journal.pone.0017156.


Metabolic biomarker based BRAFV600 mutation association and prediction in melanoma.

Saadani H, van der Hiel B, Aalbersberg EA, Zavrakidis I, Haanen JBAG, Hoekstra OS, Boellaard R, Stokkel MPM.

J Nucl Med. 2019 Sep 3. pii: jnumed.119.228312. doi: 10.2967/jnumed.119.228312. [Epub ahead of print]


Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.

Wick W, Meisner C, Hentschel B, Platten M, Schilling A, Wiestler B, Sabel MC, Koeppen S, Ketter R, Weiler M, Tabatabai G, von Deimling A, Gramatzki D, Westphal M, Schackert G, Loeffler M, Simon M, Reifenberger G, Weller M.

Neurology. 2013 Oct 22;81(17):1515-22. doi: 10.1212/WNL.0b013e3182a95680. Epub 2013 Sep 25.


Noninvasive IDH1 mutation estimation based on a quantitative radiomics approach for grade II glioma.

Yu J, Shi Z, Lian Y, Li Z, Liu T, Gao Y, Wang Y, Chen L, Mao Y.

Eur Radiol. 2017 Aug;27(8):3509-3522. doi: 10.1007/s00330-016-4653-3. Epub 2016 Dec 21.


Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.

Yin AA, He YL, Etcheverry A, Liu YH, Aubry M, Barnholtz-Sloan J, Liu BL, Mosser J, Lu ZF, Zhang X.

Clin Epigenetics. 2019 May 14;11(1):76. doi: 10.1186/s13148-019-0670-9.


MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response.

Switzeny OJ, Christmann M, Renovanz M, Giese A, Sommer C, Kaina B.

Clin Epigenetics. 2016 May 5;8:49. doi: 10.1186/s13148-016-0204-7. eCollection 2016.


Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status.

Ou D, Blanchard P, Rosellini S, Levy A, Nguyen F, Leijenaar RTH, Garberis I, Gorphe P, Bidault F, Ferté C, Robert C, Casiraghi O, Scoazec JY, Lambin P, Temam S, Deutsch E, Tao Y.

Oral Oncol. 2017 Aug;71:150-155. doi: 10.1016/j.oraloncology.2017.06.015. Epub 2017 Jun 26.


Supplemental Content

Support Center